Article Text

Download PDFPDF
Cardiovascular registries: a novel platform for randomised clinical trials
  1. Stefan James1,
  2. Ole Fröbert2,
  3. Bo Lagerqvist1
  1. 1Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
  2. 2Örebro University Hospital, Örebro, Sweden
  1. Correspondence to Dr Stefan James, Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden; stefan.james{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Registries in cardiovascular medicine in general, and within interventional cardiology in particular, have gained more attention in medical journals over the past few years. By consecutive enrolment of complete patient populations, the methodology is a powerful tool for describing healthcare, including the complications and benefits of different therapies. However, it is very important to be cautious in the interpretation of the comparison of outcomes between different treatment alternatives in observational studies and always consider them non-definitive and hypothesis generating. In order to avoid selection bias, randomisation of patients may be included within a clinical registry, combining some of the most important features of a prospective randomised trial with the key strengths of a large scale clinical registry. Thereby prospective use of quality registries could potentially revolutionise clinical trials by the fast inclusion of large patient numbers, focus on hard endpoints and complete follow-up, and at a fraction of the costs of today's randomised controlled trials.

Good clinical practice should be based on sound evidence derived from well-conducted studies. The highest levels of scientific clinical evidence stem from prospective randomised clinical trials. The European Society of Cardiology and other guideline committees and authorities generally require more than one adequate prospective randomised study for giving the procedure the highest class of recommendation reflecting the need for independent confirmation of experimental results. A single clinical experimental finding of efficacy, unsupported by other independent evidence, is not considered adequate scientific support for a definitive conclusion of efficacy. In the medical field and particularly within cardiology, an increasing number of pharmaceutical agents, medical devices and clinical procedures are tested in appropriately designed prospective randomised trials. Despite this, only about half the recommendations given in international guidelines are class one recommendations based on prospective randomised trials,1 and a large proportion of recommendations are based on …

View Full Text


  • Competing interests SJ has received institutional research grants and honoraria from Terumo Inc., Medtronic Inc., Boston Scientific, Vascular Solutions, Abbot Vascular, Eli Lilly, Astra Zeneca, BMS and Merck.

  • Provenance and peer review Commissioned; internally peer reviewed.